ERYTECH reports additional positive Phase III results from clinical study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia

ERYTECH reports additional positive Phase III results from the pivotal study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia.

Menu